🇺🇸 FDA
Patent

US 11920169

Compositions for linking DNA-binding domains and cleavage domains

granted A61PA61P31/00A61P35/00

Quick answer

US patent 11920169 (Compositions for linking DNA-binding domains and cleavage domains) held by Sangamo Therapeutics, Inc. expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61P, A61P31/00, A61P35/00, A61P43/00